Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nexagon in corneal persistent epithelial defects
NCT04081103Phase 2Terminated
- Sponsor
- Glaukos Corporation
- Start
- Jun 2020
- Primary completion
- Feb 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of lufepirsen in corneal persistent epithelial defect (PED), sponsored by Glaukos Corporation. Started Jun 2020; status: terminated.
02
Drugs
lufepirsen
03
Conditions
corneal persistent epithelial defect (PED)
Beyond the preview
Go deeper on NCT04081103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04081103.